NCT00412646View on ClinicalTrials.gov

TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

260

Participants

Timeline

Start Date

June 30, 2002

Study Completion Date

November 30, 2006

Conditions

Anti-Retroviral AgentsHIV-1

Interventions

DRUG

TMC125

All Listed Sponsors

lead

Tibotec Pharmaceuticals, Ireland

INDUSTRY

NCT00412646 - TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients | Biotech Hunter | Biotech Hunter